US Stock MarketDetailed Quotes

BRNS Barinthus Biotherapeutics

Watchlist
  • 0.986
  • +0.031+3.25%
Close Nov 29 13:00 ET
  • 0.922
  • -0.064-6.52%
Post 17:01 ET
39.66MMarket Cap-661P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 15 10:03
    NEWS
    $Barinthus Biotherapeutics (BRNS.US)$
    Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
    Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial showing enhanced results when combining imdusiran, VTP-300, and low-dose nivolumab in treating chronic hepatitis B virus. 23% of participants receiving this combination achieved HBsAg l...
    Jaguar8
    Jaguar8
    Oct 31 07:22
    NEWS
    $Barinthus Biotherapeutics (BRNS.US)$
    Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
    Barinthus Biotherapeutics (NASDAQ: BRNS) announced that updated clinical data from its chronic hepatitis B program will be presented at The Liver Meeting® 2024 in San Diego. The late-breaking presentation will focus on VTP-300 combined with low-dose nivolumab and its association with HBsAg loss in specific chronic hepatitis B patien...
    Trytosaveabit
    Trytosaveabit
    Oct 21 18:10
    Watching for upcoming data release!
    $Barinthus Biotherapeutics (BRNS.US)$ •In the fourth quarter of 2024, the Company expects to:
    ◦VTP-300 (HBV):
    ▪Announce updated interim data from HBV003, our Phase 2b trial evaluating additional dosing of VTP-300 and timing of PD-1 inhibition, in people with CHB on NUC therapy.
    ▪Announce updated interim data from the Phase 2a AB-729-202 clinical trial evaluating the combination of VTP-300 and Arbutus’ imdusiran, in people with CHB on NUC therapy.
    Jaguar8
    Jaguar8
    Oct 1 07:07
    NEWS
    $Barinthus Biotherapeutics (BRNS.US)$
    Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
    • Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.
    • Interim data update for HBV003 anticipated in Q4 2024.
    • Data update for PCA001 anticipated in H1 2025.
    OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus B...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data